Literature DB >> 25817838

A critical and previously unsuspected role for doublecortin at the neuromuscular junction in mouse and human.

F Bourgeois1, J Messéant1, E Kordeli1, J M Petit2, P Delers1, N Bahi-Buisson3, V Bernard4, S M Sigoillot1, C Gitiaux3, M Stouffer5, F Francis5, C Legay6.   

Abstract

Mutations in the microtubule-associated protein doublecortin (DCX) cause type I (X-linked or XLIS) lissencephaly in hemizygous males and subcortical band heterotopia (SBH) in females, with defects in neuron migration during development affecting cortical lamination. We found that besides its well-established expression in migrating neurons of the brain, doublecortin (Dcx in mice) is also expressed in motor neurons and skeletal muscle in embryonic neuromuscular junctions (NMJs), raising the possibility of a role in synaptogenesis. Studies with whole-mount preparations of embryonic mouse diaphragm revealed that loss of Dcx leads to abnormal presynaptic arborization and a significantly increased incidence of short axonal extensions beyond innervated acetylcholine receptor (AChR) clusters in the developing NMJ. This phenotype, albeit relatively mild, suggests that Dcx contributes to a stop/stabilizing signal at the synapse, which normally limits further axonal growth following establishment of synaptic contact with the postsynaptic element. Importantly, we also identified abnormal and denervated NMJs in a muscle biopsy from a 16-year-old female patient with SBH, showing both profound presynaptic and postsynaptic morphological defects. Overall, these combined results point to a critical role of doublecortin in the formation of the NMJ.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Doublecortin; Lissencephaly type I; Neuromuscular junction; Synapse formation

Mesh:

Substances:

Year:  2015        PMID: 25817838     DOI: 10.1016/j.nmd.2015.01.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.

Authors:  Christina Wei; Lauren Stock; Leila Valanejad; Zachary A Zalewski; Rebekah Karns; Jack Puymirat; David Nelson; David Witte; Jim Woodgett; Nikolai A Timchenko; Lubov Timchenko
Journal:  FASEB J       Date:  2018-01-05       Impact factor: 5.191

2.  Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.

Authors:  Mei Wang; Wen-Chin Weng; Lauren Stock; Diana Lindquist; Ana Martinez; Genevieve Gourdon; Nikolai Timchenko; Mike Snape; Lubov Timchenko
Journal:  Mol Cell Biol       Date:  2019-10-11       Impact factor: 4.272

Review 3.  Synaptic Homeostasis and Its Immunological Disturbance in Neuromuscular Junction Disorders.

Authors:  Masaharu Takamori
Journal:  Int J Mol Sci       Date:  2017-04-24       Impact factor: 5.923

4.  Transcriptome analysis using patient iPSC-derived skeletal myocytes: Bet1L as a new molecule possibly linked to neuromuscular junction degeneration in ALS.

Authors:  Eileen M Lynch; Samantha Robertson; Claire FitzGibbons; Megan Reilly; Colton Switalski; Adam Eckardt; Sin-Ruow Tey; Koji Hayakawa; Masatoshi Suzuki
Journal:  Exp Neurol       Date:  2021-07-24       Impact factor: 5.330

Review 5.  Molecular Mechanisms Regulating the Dendritic Development of Newborn Olfactory Bulb Interneurons in a Sensory Experience-Dependent Manner.

Authors:  Sei-Ichi Yoshihara; Hiroo Takahashi; Akio Tsuboi
Journal:  Front Neurosci       Date:  2016-01-12       Impact factor: 4.677

6.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

7.  Amygdala DCX and blood Cdk14 are implicated as cross-species indicators of individual differences in fear, extinction, and resilience to trauma exposure.

Authors:  M E Maheu; S Sharma; G King; S A Maddox; A Wingo; A Lori; V Michopoulos; R Richardson; K J Ressler
Journal:  Mol Psychiatry       Date:  2021-11-02       Impact factor: 13.437

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.